Biotech

All Articles

AstraZeneca posts data on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has discussed a very early examine the performance of its in-house antibody-drug conjug...

iTeos- GSK's TIGIT celebrity reveals relevant enhancement

.After announcing a stage 3 launch based on favorable midstage outcomes, iTeos and also GSK are ulti...

More collaborative FDA can increase rare condition R&ampD: report

.The FDA ought to be much more open as well as collective to unleash a surge in commendations of unc...

Zenas, MBX, Bicara scalp to Nasdaq in very hot day for biotech IPOs

.It is actually an uncommonly active Friday for biotech IPOs, with Zenas BioPharma, MBX as well as B...

Atea's COVID antiviral falls short to stop hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has stopped working one more COVID-19 trial, yet the biotech still ...

Neurocrine's bid to spare schizophrenia prospect falls short

.Neurocrine Biosciences' schizophrenia course pivot has actually neglected. The biotech was not able...

Sanofi pays $110M upfront for late-stage radioligand therapy

.Sanofi has made a late access to the radioligand celebration, paying for one hundred million europe...

F 2G rears $100M for second try to get brand-new antifungal to market

.After F2G's 1st effort to get a brand-new class of antifungal to market was actually derailed due t...

Moderna targets $1.1 B in R&ampD investing cuts, drops 5 courses among productivity pressures

.Moderna has sworn to cut R&ampD investing by $1.1 billion by 2027. The selection to shrink the budg...

Sanofi's $80M bet on Key dystrophy medication ends in period 3 go belly up

.Merely 4 months after Sanofi wager $80 thousand in upfront money on Key Therapies' losmapimod, the ...